Premium
Dual targeting of Bruton tyrosine kinase and CD 52 induces minimal residual disease‐negativity in the bone marrow of poor‐prognosis chronic lymphocytic leukaemia patients but is associated with opportunistic infections – Results from a phase I study
Author(s) -
Winqvist Maria,
Palma Marzia,
Heimersson Kia,
Mellstedt Håkan,
Österborg Anders,
Lundin Jeanette
Publication year - 2018
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.14836
Subject(s) - medicine , ibrutinib , chronic lymphocytic leukemia , minimal residual disease , oncology , alemtuzumab , common terminology criteria for adverse events , cytopenia , immunology , adverse effect , gastroenterology , bone marrow , leukemia , transplantation